ArticleAnnals of translational medicine2021

Cost-effectiveness analysis of camrelizumab in the second-line treatment for advanced or metastatic esophageal squamous cell carcinoma in China.

Fan Yang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.